Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?

Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than... Purpose of reviewAn increasing body of evidence suggests that nonneutralizing Fc effector functions including antibody-dependent cellular cytotoxicity (ADCC) contribute to protection against HIV-1 acquisition. We discuss recent advances in anti-HIV-1 ADCC research with a particular focus on ADCC mediated by Env-specific antibodies in vitro and in vivo, the curative potential of HIV-1-specific ADCC antibodies and the mechanisms of HIV-1 resistance to ADCC.Recent findingsADCC activities of broadly neutralizing and nonneutralizing monoclonal antibody panels were recently characterized in vitro against several lab-adapted and primary isolates of HIV-1. ADCC activity of these monoclonal antibodies generally correlated with binding to infected cells and were greater against the lab-adapted strains compared with primary HIV-1 isolates. Several recent studies in mouse and macaque models of HIV-1 infection suggest Fc-mediated effector functions contribute to the protective efficacy of broadly neutralizing antibodies and exert immune pressure on HIV-1 in vivo.SummaryAn increasing body of evidence suggests that ADCC-mediating antibodies, particularly when combined with neutralizing functions, can facilitate prevention and control of HIV-1. The precise mechanisms of partial protection conferred by nonneutralizing antibodies in vivo remain unclear and will need to be fully investigated in order to realize their full potential for HIV-1 vaccines. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/anti-hiv-1-antibody-dependent-cellular-cytotoxicity-is-there-more-to-5ZKOJ5NWxT

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000439
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewAn increasing body of evidence suggests that nonneutralizing Fc effector functions including antibody-dependent cellular cytotoxicity (ADCC) contribute to protection against HIV-1 acquisition. We discuss recent advances in anti-HIV-1 ADCC research with a particular focus on ADCC mediated by Env-specific antibodies in vitro and in vivo, the curative potential of HIV-1-specific ADCC antibodies and the mechanisms of HIV-1 resistance to ADCC.Recent findingsADCC activities of broadly neutralizing and nonneutralizing monoclonal antibody panels were recently characterized in vitro against several lab-adapted and primary isolates of HIV-1. ADCC activity of these monoclonal antibodies generally correlated with binding to infected cells and were greater against the lab-adapted strains compared with primary HIV-1 isolates. Several recent studies in mouse and macaque models of HIV-1 infection suggest Fc-mediated effector functions contribute to the protective efficacy of broadly neutralizing antibodies and exert immune pressure on HIV-1 in vivo.SummaryAn increasing body of evidence suggests that ADCC-mediating antibodies, particularly when combined with neutralizing functions, can facilitate prevention and control of HIV-1. The precise mechanisms of partial protection conferred by nonneutralizing antibodies in vivo remain unclear and will need to be fully investigated in order to realize their full potential for HIV-1 vaccines.

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Mar 1, 2018

References

  • Broadly neutralizing antibodies to HIV and their role in vaccine design
  • Use of broadly neutralizing antibodies for HIV-1 prevention
  • Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120
  • Fc receptor but not complement binding is important in antibody protection against HIV
  • Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
  • Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques
  • Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
  • Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
  • Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model
  • Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies in vivo
  • Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
  • Immune-correlates analysis of an HIV-1 vaccine efficacy trial
  • HIV-specific antibody immunity mediated through NK cells and monocytes
  • Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils
  • Identification and specificity of broadly neutralizing antibodies against HIV
  • Antibody functional assays as measures of Fc receptor-mediated immunity to HIV - new technologies and their impact on the HIV vaccine field
  • Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies
  • Elimination of HIV-1-infected cells by broadly neutralizing antibodies
  • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes
  • Lack of ADCC breadth of human nonneutralizing anti-HIV-1 antibodies
  • Nonneutralizing antibodies targeting the V1V2 domain of HIV exhibit strong antibody-dependent cell-mediated cytotoxic activity
  • Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
  • Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection
  • Targeting Trojan Horse leukocytes for HIV prevention
  • Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission
  • Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies
  • Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
  • Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
  • Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice
  • Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein
  • Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
  • Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure
  • Human nonneutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques
  • Nonneutralizing antibodies alter the course of HIV-1 infection in vivo
  • Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
  • HIV: shock and kill
  • Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
  • Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
  • The depsipeptide romidepsin reverses HIV-1 latency in vivo
  • Antibody-dependent effector functions against HIV decline in subjects on antiretroviral therapy
  • Effect of combination antiretroviral therapy on HIV-1-specific antibody-dependent cellular cytotoxicity responses in subtype B- and subtype C-infected cohorts
  • Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption
  • Mechanisms of HIV-1 resistance to ADCC
  • Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding
  • A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor
  • Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity
  • Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity
  • HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells
  • Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity
  • The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals
  • Nef proteins from HIV-1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity
  • Impaired downregulation of NKG2D ligands by Nef proteins from elite controllers sensitizes HIV-1-infected cells to antibody-dependent cellular cytotoxicity
  • Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120
  • CD4 mimetics sensitize HIV-1-infected cells to ADCC
  • Antibody-dependent cellular cytotoxicity against reactivated HIV-1-infected cells
  • Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
  • Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
  • Dimeric Fcgamma receptor enzyme-linked immunosorbent assay to study HIV-specific antibodies: a new look into breadth of Fcgamma receptor antibodies induced by the RV144 Vaccine Trial
  • Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design
  • Polyfunctional antibodies in HIV infection and vaccination
  • Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
  • Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology
  • A functional role for antibodies in tuberculosis
  • Systems serology for evaluation of HIV vaccine trials
  • HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV